InvestorsHub Logo
Followers 30
Posts 2774
Boards Moderated 4
Alias Born 10/24/2015

Re: Watts Watt post# 145

Sunday, 07/11/2021 1:16:08 PM

Sunday, July 11, 2021 1:16:08 PM

Post# of 245

Armed with these encouraging preliminary data, and with more data on the way, Adaptimmune is gearing up for its first regulatory filing for afami-cel as a treatment for advanced synovial sarcoma in 2022.



SPEARHEAD-1 full data will be at CTOS.

Meanwhile, the biotech also has plans to expand into several additional solid tumor types, such as liver, lung, and head and neck cancers.



A second registration-directed PhII (in esophageal or esophagogastric junction) will open soon and trials are already ongoing in HCC (data at ILCA), lung and H&N (data at ESMO)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADAP News